论文部分内容阅读
Objective: A previous study demonstrated that non-anthracycline-containing docetaxel plus cyclophosphamide(TC) regimen was inferior to docetaxel, anthracycline and cyclophosphamide(TAC) in neoadjuvant treatment of triple-negative breast cancer(TNBC) and h